Matt invests in artificial intelligence, quantum technology, and deep tech, with holdings spanning aerospace, healthcare, and energy. He operates at Venture Science and has backed companies including Axiom Space, PsiQuantum, and Lightmatter.
Twin Path Ventures led the seed financing for the Belfast biotechnology firm to accelerate its preclinical discovery programmes.
"Ten years ago, I began combining financial modeling expertise with computational biology to create a drug discovery platform. Evolution has spent billions of years perfecting natural defense mechanisms, and now we’re using AI to unlock this wisdom. This isn’t just professional for me; my father died from a drug-resistant infection our healthcare system couldn’t treat. At Queen’s, I built AMPLY to tackle deadly diseases differently, creating technology that will save lives when current treatments fail."
The company has raised capital from international strategic and financial partners to accelerate its expansion across multiple industries.
"This landmark investment from world-class investors is a tremendous validation of our strategy to apply self-driving technology where there is persistent and urgent demand—in supply chains, industrial sectors, and in decongesting our cities."
The investment coincides with a commercial partnership to integrate autonomous vehicle software into warehouse and delivery operations.
"We are excited about the opportunity to work with Oxbotica to develop a wide range of autonomous solutions that truly have the potential to transform both our and our partners’ CFC and service delivery operations, while also giving all end customers the widest range of options and flexibility."
The Series B round was led by bp ventures with participation from a global investor syndicate.
"We are very excited about the amazing endorsement we have received from new and existing investors. This round of investment marks a key chapter in Oxbotica’s continued growth and pushes us forward in commercialising our autonomous software today, through key strategic go-to-market partnerships. The high-quality and global footprint of our investors cements our position as a leader in autonomy. We will use funds raised to accelerate the global deployment of our transformative technology."
